SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education
Speaker
Balazs Halmos, MD
Professor, Department of Medicine (Oncology)
Albert Einstein College of Medicine
Director of Thoracic/Head and Neck Oncology and Clinical Cancer Genomics
Montefiore Medical Center
Bronx, NY

Course Director and Moderator
Rasim A. Gucalp, MD, FACP
Professor, Department of Medicine (Oncology)
Albert Einstein College of Medicine
Montefiore Medical Center
Director, Hematology/Oncology Fellowship Program
Bronx, NY

CME Reviewer
Victor Hatcher, PhD
Associate Dean for Continuing Medical Education
Professor, Department of Biochemistry
Professor, Department of Medicine
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

Title
: Targeting Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer: Advances in Treatment
Activity/Course #:
: NCME382
Cost:
: Free
Release/Start Date:
: Jun 15 2019
Expiration Date:
: Jun 14 2020
Topics:
: Cancer
Target Audience:
: Oncology and other clinicians that care for patients with EGFR NSCLC
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
It is estimated that more than 234,000 cases of lung cancer will be diagnosed and more than 154,000 lung cancer related deaths in 2018. Approximately 80-85% of patients with lung cancer are diagnosed with NSCLC. Historically, first-line treatment for NSCLC has been platinum-based chemotherapy. However, with the advent of genomic testing, the treatment of many cancers, including NSCLC, has transformed to a more personalized approach.

This activity will explore the need for testing for epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer, the role of mechanisms of EGFR inhibitors, development of an individualized treatment strategy and the adverse effects of EGFR inhibitor treatment.

This webcast was recorded live at the Conversations in Oncology 2019 and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Recognize the need for testing for epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC)
  2. Recognize the role of mechanisms of resistance of EGFR inhibitors in the treatment of patients with NSCLC
  3. Integrate the latest clinical data on EGFR inhibitors when developing an individualized treatment strategy for patients with NSCLC
  4. Identify the adverse effects of EGFR inhibitor treatment in NSCLC

 How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate
Sponsored and Certified By
Albert Einstein College of Medicine
Accreditation Designation Statement
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities.

The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship with a commercial interest* during the past 12-month period proceeding the time that the individual is asked to assume a role controlling content of this CME activity. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Faculty disclosures are provided below.

*The ACCME defines a commercial interest as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providing clinical service directly to patients to be commercial interests - unless the provider of the clinical service is owned, or controlled by, an ACCME-defined commercial interest.

Speaker
Dr. Halmos had received Research funding (to institution) from: AbbVie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli-Lilly, GlaxoSmithKline, Guardant Health, Merck, Mirati, Novartis, Pfizer, and Takeda. He has also been consulting for Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Foundation Medicine, Genentech, Guardant Health, Ignyta, Pfizer, Novartis, and Spectrum.

Dr. Halmos has indicated that his reported relationships will not impact his ability to present an unbiased presentation.

Course Director and Moderator
Dr. Gucalp has no relevant conflicts of interest with any ACCME-defined commercial interest.

CME Reviewer
Dr. Hatcher has no relevant conflicts of interest with any ACCME-defined commercial interest.

Activity Planning Committee
Gregg Sherman, MD, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Josh Kilbridge, Medical Writer, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Michelle Frisch, MPH, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Daniela Hiedra, BA, has no relevant conflicts of interest with any ACCME-defined commercial interest.

Sandy Bihlmeyer, MEd, has no relevant conflicts of interest with any ACCME-defined commercial interest.
Commercial Support
This educational activity is supported by an educational grant from Boehringer Ingelheim